Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivations
Influenza remains a serious global health concern, causing significant morbidity and mortality each year. Vaccination is crucial to mitigate its impact, but requires rapid and efficient manufacturing strategies to handle timing and supply. Traditionally relying on egg-based production, the field has...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2373521 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849717333609676800 |
|---|---|
| author | Tilia Zinnecker Udo Reichl Yvonne Genzel |
| author_facet | Tilia Zinnecker Udo Reichl Yvonne Genzel |
| author_sort | Tilia Zinnecker |
| collection | DOAJ |
| description | Influenza remains a serious global health concern, causing significant morbidity and mortality each year. Vaccination is crucial to mitigate its impact, but requires rapid and efficient manufacturing strategies to handle timing and supply. Traditionally relying on egg-based production, the field has witnessed a paradigm shift toward cell culture-based methods offering enhanced flexibility, scalability, and process safety. This review provides a concise overview of available cell substrates and technological advancements. We summarize crucial steps toward process intensification – from roller bottle production to dynamic cultures on carriers and from suspension cultures in batch mode to high cell density perfusion using various cell retention devices. Moreover, we compare single-use and conventional systems and address challenges including defective interfering particles. Taken together, we describe the current state-of-the-art in cell culture-based influenza virus production to sustainably meet vaccine demands, guarantee a timely supply, and keep up with the challenges of seasonal epidemics and global pandemics. |
| format | Article |
| id | doaj-art-213ffb655321467696ef2e5d66c3f39b |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-213ffb655321467696ef2e5d66c3f39b2025-08-20T03:12:41ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2373521Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivationsTilia Zinnecker0Udo Reichl1Yvonne Genzel2Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, GermanyBioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, GermanyBioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg, GermanyInfluenza remains a serious global health concern, causing significant morbidity and mortality each year. Vaccination is crucial to mitigate its impact, but requires rapid and efficient manufacturing strategies to handle timing and supply. Traditionally relying on egg-based production, the field has witnessed a paradigm shift toward cell culture-based methods offering enhanced flexibility, scalability, and process safety. This review provides a concise overview of available cell substrates and technological advancements. We summarize crucial steps toward process intensification – from roller bottle production to dynamic cultures on carriers and from suspension cultures in batch mode to high cell density perfusion using various cell retention devices. Moreover, we compare single-use and conventional systems and address challenges including defective interfering particles. Taken together, we describe the current state-of-the-art in cell culture-based influenza virus production to sustainably meet vaccine demands, guarantee a timely supply, and keep up with the challenges of seasonal epidemics and global pandemics.https://www.tandfonline.com/doi/10.1080/21645515.2024.2373521Influenza virus productionprocess developmentcell culture-based viral vaccine manufacturingprocess intensificationhigh cell densityperfusion cultivations |
| spellingShingle | Tilia Zinnecker Udo Reichl Yvonne Genzel Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivations Human Vaccines & Immunotherapeutics Influenza virus production process development cell culture-based viral vaccine manufacturing process intensification high cell density perfusion cultivations |
| title | Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivations |
| title_full | Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivations |
| title_fullStr | Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivations |
| title_full_unstemmed | Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivations |
| title_short | Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivations |
| title_sort | innovations in cell culture based influenza vaccine manufacturing from static cultures to high cell density cultivations |
| topic | Influenza virus production process development cell culture-based viral vaccine manufacturing process intensification high cell density perfusion cultivations |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2373521 |
| work_keys_str_mv | AT tiliazinnecker innovationsincellculturebasedinfluenzavaccinemanufacturingfromstaticculturestohighcelldensitycultivations AT udoreichl innovationsincellculturebasedinfluenzavaccinemanufacturingfromstaticculturestohighcelldensitycultivations AT yvonnegenzel innovationsincellculturebasedinfluenzavaccinemanufacturingfromstaticculturestohighcelldensitycultivations |